High-Flying Biotech Valuations Are Falling – And Maybe That’s A Good Thing
Big Pharma Focused On Science, Not Prior Funding
Executive Summary
Venture capitalists speaking at Biocom’s Global Life Science Partnering Conference looked forward to a return to rational valuations that could enable better returns for investors and pharma buyers.
You may also be interested in...
Frazier Sees Opportunity For New $987m Fund Despite Financial Market Turmoil
Frazier Life Sciences managing partner James Topper described how the firm will use its 11th fund to launch new companies, support growing firms and take advantage of public market opportunities.
Deal Watch: AbbVie Adds Neuroscience Heft With Syndesi Acquisition
AbbVie pays $130m up front with up to $870m in earnout potential for UCB spinout focused on SV2A modulators. BioNTech gets rights to preclinical TCR candidates for solid tumors from Medigene.
Ex-Eylea Leader Launches Biotech Targeting Untapped Eye Market
Former Bayer executive Rafiq Hasan believes the start-up’s gene therapy candidate can open up treatment to millions of patients with dry AMD and geographic atrophy.